Novo Nordisk's Oral Semaglutide Succeeds In First Phase III, But Prompts Questions
Executive Summary
In PIONEER 1, weight loss results for the oral version of the GLP-1 agonist were somewhat disappointing and lack of detail in the top-line release prompts concerns about compliance.
You may also be interested in...
Novo Nordisk Touts First-Line Potential For Oral Semaglutide
Novo's oral GLP-1 receptor agonist has a lot going for it in diabetes based on the latest data, but still needs to prove cardiovascular benefit; a new large outcomes study is now in the works.
ADA Meeting's Around The Corner: Five Things To Watch For
Among other debates at the American Diabetes Association annual meeting, clinicians will discuss the future of cardiovascular outcomes studies for diabetes drugs – whether they should maintain course or are due for an overhaul.
Novo's Oral Semaglutide Passes PIONEER 2, But Weight Loss Result A Bit Disappointing
In second Phase III diabetes study to report, oral GLP-1 agonist semaglutide misses some weight loss goals when compared with Boehringer/Lilly's SGLT-2 inhibitor Jardiance.